LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Items 301–400 of 1,000
Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma
Li, C. M.-C., Chen, G., Dayton, T. L., Kim-Kiselak, C., Hoersch, S., Whittaker, C. A., Bronson, R. T., Beer, D. G., Winslow, M. M., & Jacks, T. (2013) · Genes & Development · doi:10.1101/gad.222745.113 · Cited by 81
“…cell lines in allowing molecular characterization of the cell state changes that accompany tumor progression and metastasis and is representative of recent developments of animal models for lung adenocarcinoma (Jackson et al. 2005; Politi et al. 2006; Dankort et al. 2007; Ji et al. 2007).”
BackgroundSelf-citationZhu, A. X., & Hezel, A. F. (2011) · Hepatology · doi:10.1002/hep.24145 · Cited by 71
“STK11 is established as a key TSG in nonsmall-cell lung carcinoma (NSCLC) and to a lesser extent pancreatic cancer.(46) Additional molecular alterations found in BTC that have been generally linked with cancer are reviewed elsewhere.”
BackgroundIntact LKB1 activity is required for survival of dormant ovarian cancer spheroids
Peart, T., Valdes, Y. R., Correa, R. J. M., Fazio, E., Bertrand, M., McGee, J., Préfontaine, M., Sugimoto, A., DiMattia, G. E., & Shepherd, T. G. (2015) · Oncotarget · doi:10.18632/oncotarget.4211 · Cited by 66
“In other cancer models, LKB1 loss-of-function has been shown to accelerate tumorigenesis in conjunction with p53 [50], Kras [51], and c-myc [52], as well.”
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Xu, K., Park, D., Magis, A. T., Zhang, J., Zhou, W., Sica, G., Ramalingam, S. S., Curran, W. J., & Deng, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1012-4 · Cited by 75
Recent advances in preclinical models for lung squamous cell carcinoma
Pan, Y., Han, H., Labbe, K. E., Zhang, H., & Wong, K. (2021) · Oncogene · doi:10.1038/s41388-021-01723-7 · Cited by 74
“It was originally reported in 2007 that simultaneous activation of Kras with deletion of Lkb1, results in mixed adenocarcinoma and squamous carcinoma histology in the mouse lung [64].”
BackgroundSelf-citationNanjundan, M., Byers, L. A., Carey, M. S., Siwak, D. R., Raso, M. G., Diao, L., Wang, J., Coombes, K. R., Roth, J. A., Mills, G. B., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f2a266 · Cited by 70
Ahn, Y., Yang, Y., Gibbons, D. L., Creighton, C. J., Yang, F., Wistuba, I. I., Lin, W., Thilaganathan, N., Alvarez, C. A., Roybal, J. D., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05562-11 · Cited by 71
“These findings add to a growing list of somatic mutations that cooperate with mutant Kras to promote lung adenocarcinoma development in mice (19, 22, 28, 33, 52).”
BackgroundMarien, E., Meister, M. A., Muley, T., del Pulgar, T. G., Derua, R., Spraggins, J. M., de Plas, R. V., Vanderhoydonc, F., Machiels, J., Binda, M. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7179 · Cited by 68
“Also LKB1, which is decreased in human lung cancer [33] as well as in the L-IkkαKA/KA SCC mouse model [7], may shuttle substrates into the elongation pathway by regulating ACACA.”
BackgroundQueiroz, A. L., Dantas, E., Ramsamooj, S., Murthy, A., Ahmed, M., Zunica, E. R. M., Liang, R. J., Murphy, J., Holman, C. D., Bare, C. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32135-0 · Cited by 69
The role of LKB1 in lung cancer
Sánchez‐Céspedes, M. (2011) · Familial Cancer · doi:10.1007/s10689-011-9443-0 · Cited by 67
“[22] used a somatically activatable mutant Kras-driven model of mouse lung cancer to obtain convincing evidence that Lkb1-deficiency cooperates with Kras in lung cancer development to yield tumors with shorter latency, an expanded histological spectrum and more frequent metastasis compared with those lacking other can…”
Sima, N., Cheng, X., Ye, F., Ma, D., Xie, X., & Lü, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074594 · Cited by 67
“Several studies [9,10,14,25,34-38] have shown that specific siRNAs targeting mRNA of NEDD9 gene are able to down-regulate expression of NEDD9.”
BackgroundThe Molecular Biology of Brain Metastasis
Rahmathulla, G., Toms, S. A., & Weil, R. J. (2012) · Journal of Oncology · doi:10.1155/2012/723541 · Cited by 68
“These molecules include ezrin (an intracellular protein necessary for the survival of osteosarcoma cells in the lung) and serine-threonine kinase 11 (STK11, or LKB1, a metastasis suppressor which regulates NEDD9 in lung cancer) [87].”
BackgroundFBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth
Zhu, X., He, P., Zhang, L., Yang, S., Zhang, H., Zhu, D., Liu, M.-D., & Yu, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1732-9 · Cited by 71
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 70
Zhang, D., Ning, J., Okon, I. S., Zheng, X., Satyanarayana, G., Song, P., Xu, S., & Zou, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03793-7 · Cited by 72
Targeting the LKB1 Tumor Suppressor
Zhao, R., & Xu, Z. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095811 · Cited by 70
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival
William, W. N., Kim, J.-S., Liu, D. D., Solis, L. M., Behrens, C., Lee, J. J., Lippman, S. M., Kim, S., Hong, W. K., Wistuba, I. I., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr036 · Cited by 63
Nagaraj, A. S., Lahtela, J., Hemmes, A., Pellinen, T., Blom, S., Devlin, J. R., Salmenkivi, K., Kallioniemi, O., Mäyränpää, M. I., Närhi, K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.059 · Cited by 64
“While others have reported the efficacy of targeting the immunosuppressive microenvironment in Kras;Lkb1 GEMMs (Koyama et al., 2016), the importance of the tumor histotype to therapeutic outcome was not addressed.”
BackgroundResultInfluentialPaired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park, S., Shim, J., Lee, B., Cho, I., Park, W., Kim, Y., Lee, S., Choi, Y., Han, J., Ahn, J. S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.024 · Cited by 66
NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition
Jin, Y., Li, F., Zheng, C., Wang, Y., Fang, Z., Guo, C., Wang, X., Liu, H., Deng, L., Li, C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28568 · Cited by 64
“LKB1 somatic mutations are frequently observed in lung cancer.(8,27,28) Recent co-clinical trial study has shown that LKB1-deficient lung tumors are intrinsically resistant to multiple drug treatments,(29) highlighting that this subset of lung cancer may represent as a unique subpopulation.”
BackgroundMethodSelf-citationHu, L., Liang, S., Chen, H., Lv, T., Wu, J., Chen, D., Wu, M. C., Sun, S., Zhang, H., You, H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617816114 · Cited by 67
Self-citationMolecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
Vassella, E., Langsch, S., Dettmer, M. S., Schlup, C., Neuenschwander, M., Frattini, M., Gugger, M., & Schäfer, S. C. (2015) · Oncotarget · doi:10.18632/oncotarget.4163 · Cited by 64
“Loss of STK11 or targeted deletion of PTEN or TGFβR1 in the oncogenic KRASG12D mouse model gave rise to ADSQ-like tumors [36].”
BackgroundHoude, V. P., Ritorto, M. S., Gourlay, R., Varghese, J., Davies, P., Shpiro, N., Sakamoto, K., & Alessi, D. R. (2014) · Biochemical Journal · doi:10.1042/bj20131324 · Cited by 56
Gene expression profiling of Non-small cell lung cancer
Singhal, S. K., Miller, D., Ramalingam, S. S., & Sun, S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.03.007 · Cited by 62
“Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto M, Shimizu E, Minna JD, Yokota J. Prevalence and specificity of LKB1 genetic alterations in lung cancers.”
BackgroundThe Hypoxic Tumor Microenvironment: Driving the Tumorigenesis of Non-Small-Cell Lung Cancer
Foster, J. G., Wong, S. C. K., & Sharp, T. V. (2014) · Future Oncology · doi:10.2217/fon.14.201 · Cited by 69
Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer
Cron, K. R., Zhu, K., Kushwaha, D. S., Hsieh, G., Merzon, D., Rameseder, J., Chen, C. C., D’Andrea, A. D., & Kozono, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073710 · Cited by 74
“These mutations are found in tumors that are particularly aggressive and resistant to therapy, and for which targeted therapies are unavailable [18,19].”
BackgroundElsum, I. A., Yates, L. L., Pearson, H. B., Phesse, T. J., Long, F., O'Donoghue, R., Ernst, M., Cullinane, C., & Humbert, P. O. (2014) · Oncogene · doi:10.1038/onc.2013.498 · Cited by 60
Lan, T., Arastu, S., Lam, J., Kim, H., Wang, W., Wang, S. R., Bhatt, V. D., Lopes, E. C., Hu, Z. S., Sun, M. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50157-8 · Cited by 69
“This increased aggressiveness of KL lung tumors has also been observed in preclinical mouse models 39 .”
LKB1 reduces ROS-mediated cell damage via activation of p38
Xu, H.-G., Zhai, Y.-X., Chen, J., Lu, Y., Wang, J.-W., Quan, C.-S., Zhao, R.-X., Xiao, X., He, Q., Werle, K. D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.315 · Cited by 61
HLungDB: an integrated database of human lung cancer research
Wang, L., Xiong, Y., Sun, Y., Fang, Z., Li, L., Ji, H., & Shi, T. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp945 · Cited by 62
“Another important tumor suppressor gene is LKB1, whose loss-of-function mutation/deletion is observed in 30% lung adenocarcinomas and 20% of squamous cell carcinomas (6,7).”
BackgroundSelf-citationWhang, Y. M., Park, S. I., Trenary, I. A., Egnatchik, R. A., Fessel, J. P., Kaufman, J. M., Carbone, D. P., & Young, J. D. (2016) · Oncogene · doi:10.1038/onc.2015.140 · Cited by 61
Prognostic Significance of OCT4 Expression in Adenocarcinoma of the Lung
Zhang, X., Han, B., Huang, J., Zheng, B., Geng, Q., Aziz, F., & Dong, Q. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq066 · Cited by 61
Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories
Hynds, R. E., Frese, K. K., Pearce, D. R., Gronroos, E. C., Dive, C., & Swanton, C. (2021) · Open Biology · doi:10.1098/rsob.200247 · Cited by 66
“In LUAD, the addition of Lkb1 mutations to Kras-driven GEMMs has confirmed that they modify histology, as dual mutants give rise to LUAD, LUSC and mixed adenosquamous lesions [80].”
BackgroundInhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
Bhatt, V. D., Lan, T., Wang, W., Kong, J., Lopes, E. C., Wang, J., Khayati, K., Raju, A., Rangel, M., Lopez, E., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05592-8 · Cited by 64
“While co-mutations in KRAS and LKB1 are found in tumors of squamous cell carcinoma and adenocarcinoma, KRAS and TP53 co-mutations are found only in adenocarcinoma [10, 11].”
BackgroundVallianou, N. G., Evangelopoulos, A. A., & Kazazis, C. E. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.228 · Cited by 72
“Because of this potent connection to AMPK, LKB1 may act as a central regulator of metabolism in vivo [21-26].”
BackgroundRole of LKB1 in lung cancer development
Makowski, L., & Hayes, D. N. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604515 · Cited by 57
“To this end, we documented several interactions between LKB1 and other genes commonly altered in lung cancer in experimental animal models (Ji et al, 2007).”
Self-citationMeserve, E. E. K., & Nucci, M. R. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.01.006 · Cited by 69
Perera, S. A., Maser, R. S., Xia, H., McNamara, K., Protopopov, A., Chen, L., F.Hezel, A., Kim, C. F., Bronson, R. T., Castrillon, D. H., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn050 · Cited by 56
“This wellestablished protocol produces precursor lesions that progress into tumors >5 mm by 14 weeks post AdenoCre administration, resulting in death at a median age of 20-24 weeks [21].”
BackgroundSelf-citationLKB1 inactivation modulates chromatin accessibility to drive metastatic progression
Pierce, S. E., Granja, J. M., Corces, M. R., Brady, J. J., Tsai, M. K., Pierce, A. B., Tang, R., Chu, P., Feldser, D. M., Chang, H. Y., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00728-4 · Cited by 59
Gailite, I., Aerne, B. L., & Tapon, N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505512112 · Cited by 55
Li, Y., Liu, J., Wang, Z., Jin, J., Liu, Y., Chen, C., & Tang, Z. (2020) · Advanced Materials · doi:10.1002/adma.201907718 · Cited by 59
Arbelaez, C. A., Estrada, J., Gessner, M. A., Glaus, C., Morales, A. B., Mohn, D., Phee, H., Lipford, J. R., & Johnston, J. A. (2020) · npj Vaccines · doi:10.1038/s41541-020-00253-9 · Cited by 56
AMP-Activated Protein Kinase: Do We Need Activators or Inhibitors to Treat or Prevent Cancer?
Russell, F. M., & Hardie, D. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010186 · Cited by 59
Yu, Y., Cai, J., Tu, B., Wu, L., Zhao, Y., Liu, X., Li, L., McNutt, M. A., Feng, J., He, Q., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.015289 · Cited by 58
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma
Gilbert-Ross, M., Konen, J., Koo, J., Shupe, J., Robinson, B. S., Wiles, W. G., Huang, C., Martin, W. D., Behera, M., Smith, G. H., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90487 · Cited by 57
Li, C., Gao, Z., Li, F., Li, X., Sun, Y., Wang, M., Li, D., Wang, R., Li, F., Fang, R., et al. (2015) · Scientific Reports · doi:10.1038/srep14237 · Cited by 59
Self-citationParikh, A. B., Kozuch, P. S., Rohs, N. C., Becker, D. J., & Levy, B. P. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0511-7 · Cited by 56
Xiao, Z., Sperl, B., Ullrich, A., & Knyazev, P. G. (2014) · Oncotarget · doi:10.18632/oncotarget.2657 · Cited by 56
“Additionally, the mutation frequencies of KRAS, anaplastic lymphoma kinase (ALK) and liver kinase B1 (LKB1) are approximately 25%, 3-7% and 15-30% of NSCLCs, respectively [4, 5].”
BackgroundKim, B. R., de Laar, E. V., Cabanero, M., Tarumi, S., Hasenöder, S., Wang, D. Y. Q., Virtanen, C., Suzuki, T., Bandarchi, B., Sakashita, S., et al. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002581 · Cited by 58
“Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway
Best, S. A., & Sutherland, K. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1496756 · Cited by 54
“While combined loss of Lkb1, detected in 17% of KRAS-mutant lung ADC [4,34], accelerates Kras tumorigenesis and promotes ADC to SqCC transformation [39,40].”
BackgroundHardie, D. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010819 · Cited by 55
Liang, M.-C., Ma, J., Chen, L., Kozlowski, P., Qin, W., Li, D., Goto, J., Shimamura, T., Hayes, D. N., Meyerson, M., et al. (2010) · Oncogene · doi:10.1038/onc.2009.452 · Cited by 54
Self-citationCilia and cilia-associated proteins in cancer
Seeger‐Nukpezah, T., Little, J. L., Serzhanova, V., & Golemis, E. A. (2013) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2013.03.004 · Cited by 55
“Many non-small cell lung cancers (NSCLC) lacking LKB1 overexpress NEDD9, which contributes to increased metastasis, and is predicted to activate AURKA and support ciliary disassembly [21,30].”
BackgroundThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis
Ochieng, J., Nangami, G. N., Ogunkua, O., Miousse, I. R., Koturbash, I., Odero-Marah, V., McCawley, L. J., Nangia‐Makker, P., Ahmed, N., Luqmani, Y. A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv034 · Cited by 55
“As a result, HEF1/NEDD9/CAS-L regulates migratory processes as demonstrated in a melanoma cell line (227); moreover, in several human cancers such as melanoma, glioblastoma (228) and lung tumors (229), increased HEF1/NEDD9/CAS-L expression was found to correlate with the metastasis potential of those tumors.”
BackgroundLKB1 promotes metabolic flexibility in response to energy stress
Parker, S. J., Svensson, R. U., Divakaruni, A. S., Lefebvre, A. E. Y. T., Murphy, A. N., Shaw, R. J., & Metallo, C. M. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.12.010 · Cited by 57
“…observe minimal impacts of LKB1 expression on cell proliferation in culture (Faubert et al., 2014; Whang et al., 2016), several studies using in vivo cancer models have indicated that LKB1 loss significantly enhances tumor growth (Ji et al., 2007; Kottakis et al., 2016; Shackelford et al., 2013).”
BackgroundHaines, E., Chen, T., Kommajosyula, N., Chen, Z., Herter-Sprie, G. S., Cornell, L., Wong, K.-K., & Shapiro, G. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25803 · Cited by 51
“adeno-Cre intranasally as previously described [49].”
Self-citationLysyl Oxidase Like 1: Biological roles and regulation
Greene, A. G., Eivers, S. B., Dervan, E. W. J., O'Brien, C. J., & Wallace, D. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.107975 · Cited by 57
Bonanno, L., De Paoli, A., Zulato, E., Esposito, G., Calabrese, F., Favaretto, A., Santo, A., Conte, A. D., Chilosi, M., Oniga, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2410 · Cited by 53
“Non–small cell lung cancer (NSCLC) is a relevant malignancy for this study, as LKB1 genetic inactivation has been reported in approximately 30% of cases, especially lung adenocarcinoma (8), and LKB1 has a demonstrated role in lung tumorigenesis (9, 10).”
BackgroundDupuy, F., Griss, T., Blagih, J., Bridon, G., Avizonis, D. Z., Ling, C., Dong, Z., Siwak, D. R., Annis, M. G., Mills, G. B., et al. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-18 · Cited by 54
“Our work and that of other groups [43] suggests that loss of LKB1 cooperates with oncogenes to modulate the initiation and growth properties of tumors; however, our data indicate that the impact of reducing LKB1 expression on breast cancer development is complex.”
BackgroundKlingbeil, O., Lesche, R., Gelato, K. A., Haendler, B., & Lejeune, P. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.271 · Cited by 55
“In addition, recent findings suggest that BRD4-independent rebound of MYC expression is a mechanism of acquired resistance to BET inhibitor treatment in AML models with strong c-Myc dependency.36 Exploring the potential of BET inhibition beyond regulation of theMYC oncogene, we identified the reduced expression of the…”
BackgroundInfluentialProtein kinase LKB1 promotes RAB7-mediated neuropilin-1 degradation to inhibit angiogenesis
Okon, I. S., Coughlan, K. A., Zhang, C., Moriasi, C., Ding, Y., Song, P., Zhang, W., Li, G., & Zou, M.-H. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75371 · Cited by 52
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer
Cai, H., Chew, S. K., Li, C., Tsai, M. K., Andrejka, L., Murray, C. W., Hughes, N. W., Shuldiner, E. G., Ashkin, E. L., Tang, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1325 · Cited by 54
Self-citationHistological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows
Tan, N., Li, Y., Ying, J., & Chen, W. (2024) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2024-0019 · Cited by 55
“[57] A previous study utilizing a mouse model with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant lung cancers indicated that LKB1 , also known as serine/threonine kinase (STK11), plays a significant role in the gradual transition and poor efficacy of TKIs through metabolic alterations.”
MethodHepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice
Liu, Y., Dantas, E., Ferrer, M., Miao, T., Qadiri, M., Liu, Y., Comjean, A., Davidson, E. E., Perrier, T., Ahmed, T., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01265-2 · Cited by 57
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 59
“Similar to other studies, they found that 34% of 144 human adenocarcinoma samples and 19% of squamous-cell carcinomas had inactivation of LKB1 [233, 234].”
BackgroundResultImage-guided radiotherapy platform using single nodule conditional lung cancer mouse models
Herter-Sprie, G. S., Korideck, H., Christensen, C. L., Herter, J. M., Rhee, K., Berbeco, R. I., Bennett, D. G., Akbay, E. A., Kozono, D., Mak, R. H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6870 · Cited by 53
Self-citationLKB1 and Lung Cancer: More Than the Usual Suspects
Shah, U., Sharpless, N. E., & Hayes, D. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6620 · Cited by 50
“promoter methylation, and therefore, our data do not directly address this issue ( 12 , 20).”
BackgroundSelf-citationThe CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss
Feng, Y., Wang, Y., Wang, Z., Fang, Z., Li, F., Gao, Y., Liu, H., Xiao, T., Li, F., Zhou, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1909 · Cited by 54
“NEDD9 is an important downstream mediator of lung cancer progression and metastasis evoked by Lkb1 deficiency.”
InfluentialSelf-citationATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis
Luo, L., Huang, W., Tao, R., Hu, N., Xiao, Z. J., & Luo, Z. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.034 · Cited by 56
“Secondly, somatic mutations of the LKB1 gene have been found in many other cancers, for example, in approximately 34% of lung adenocarcinomas, 19% of squamous cell carcinomas, and 20% cervical carcinomas and other cancers [6; 7; 8; 9].”
BackgroundMechanisms for nonmitotic activation of Aurora-A at cilia
Korobeynikov, V. A., Deneka, A. Y., & Golemis, E. A. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160142 · Cited by 54
WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non–Small Cell Lung Cancer
Richer, A. L., Cala, J. M., O’Brien, K., Carson, V. M., Inge, L. J., & Whitsett, T. G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3565 · Cited by 53
Zheng, X., Chi, J., Zhi, J., Zhang, H., Yue, D., Zhao, J., Li, D., Li, Y., Gao, M., & Guo, J. (2017) · Oncogene · doi:10.1038/onc.2017.354 · Cited by 51
Self-citationApplications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy
Li, Q., Qin, Z., Wang, Q., Xu, T., Yang, Y., & He, Z. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.05.006 · Cited by 59
“P53, Lkb1 and Kras are important genes related to lung cancer, and studies have shown that Lkb1 mutation can aggravate lung cancer [20].”
BackgroundBahrambeigi, S., & Shafiei‐Irannejad, V. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113787 · Cited by 52
Cong, J., Liu, R., Wang, X., Jiang, H., & Zhang, Y. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1080171 · Cited by 50
“…component of miR-634 family, demonstrating that miR-634 inhibited mTOR expression and induced apoptosis in esophageal squamous cell carcinoma (Yamamoto et al. 2014), and directly targets fibroblast growth factor receptor 3 and inhibits the growth of non-small-cell lung cancer (Ji et al. 2007).”
BackgroundThe CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non–small cell lung cancer
Rodón, L., Svensson, R. U., Wiater, E., Chun, M. G. H., Tsai, W.-W., Eichner, L. J., Shaw, R. J., & Montminy, M. (2019) · Science Advances · doi:10.1126/sciadv.aaw6455 · Cited by 48
LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor
Gao, Y., Ge, G., & Ji, H. (2011) · Protein & Cell · doi:10.1007/s13238-011-1021-6 · Cited by 53
Self-citationProgress and applications of mouse models for human lung cancer
Seranno, S. D., & Meuwissen, R. L. J. (2010) · European Respiratory Journal · doi:10.1183/09031936.00124709 · Cited by 58
Nii, T., Makino, K., & Tabata, Y. (2019) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2019.0189 · Cited by 50
Calcium-binding protein S100A14 induces differentiation and suppresses metastasis in gastric cancer
Zhu, M., Wang, H., Cui, J., Li, W., An, G., Pan, Y., Zhang, Q., Xing, R., & Lu, Y. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.297 · Cited by 49
“Tumor cell differentiation strongly correlates with a malignant phenotype.(21,22) S100 proteins are involved in these complex processes; in particular, the variation in and role of S100A14 in GC are unclear.”
BackgroundProteasome-dependent degradation of Smad7 is critical for lung cancer metastasis
Lu, T., Shen, S., Huang, Q., Fu, J., Wang, T., Pan, L., Zhang, P., Chen, G., Huang, T., Li, K., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0459-6 · Cited by 52
Liver Kinase B1 (LKB1) in the pathogenesis of epithelial cancers
Herrmann, J. L., Byekova, Y., Elmets, C. A., & Athar, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.014 · Cited by 46
“Sporadic mutations in LKB1 are common in non-small cell lung carcinoma [72,73], and studies demonstrate that it is the third most commonly mutated gene behind p53 and K-RAS.”
Yung, M. M. H., Ross, F. A., Hardie, D. G., Leung, T. H. Y., Zhan, J., Ngan, H., & Chan, D. W. (2015) · Integrative Cancer Therapies · doi:10.1177/1534735415611747 · Cited by 50
RetractedThe Tumor Suppressor Kinase LKB1: Metabolic Nexus
Bourouh, M., & Marignani, P. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.881297 · Cited by 53
“The importance of glycolysis is not only through energy production, but glycolytic intermediates are important for many anabolic processes such as nucleotide synthesis and generating ROS scavengers (Lin et al., 2015; Ju et al., 2017).”
BackgroundLKB1 controls inflammatory potential through CRTC2-dependent histone acetylation
Compton, S. E., Kitchen-Goosen, S. M., DeCamp, L. M., Lau, K. H., Mabvakure, B. M., Vos, M., Williams, K. S., Wong, K., Shi, X., Rothbart, S. B., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.04.017 · Cited by 51
Self-citationKline, E. R., Shupe, J. A., Gilbert‐Ross, M., Zhou, W., & Marcus, A. I. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444620 · Cited by 53
LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
Zhou, W., Zhang, J., & Marcus, A. I. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.06.002 · Cited by 51
“Adenocarcinoma of the lung contains the highest mutation frequency of LKB1, and LKB1 was also found to be mutated at lower frequencies in large cell and squamous cancer of the lung.(15,16) Interestingly, a recent study in a mouse model shows that Lkb1-deficient lung adenocarcinoma (ADC) progressively transdifferentiat…”
BackgroundLKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues
Chan, K. T., Asokan, S. B., King, S. J., Bo, T., Dubose, E. S., Liu, W., Berginski, M. E., Simon, J. M., Davis, I. J., Gomez, S. M., et al. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201404067 · Cited by 54
“…mutations that result in the inactivation of LKB1 are also found in sporadic cancers such as lung adenocarcinoma (Sanchez-Cespedes et al., 2002; Ji et al., 2007), cervical carcinoma (Wingo et al., 2009), pancreatic cancer (Su et al., 1999), and melanoma (Guldberg et al., 1999; Rowan et al.,…”
BackgroundSelf-citationLKB1 Controls Human Bronchial Epithelial Morphogenesis through p114RhoGEF-Dependent RhoA Activation
Xu, X., Jin, D., Durgan, J., & Hall, A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00154-13 · Cited by 48
“Mouse models of lung cancer in which mice harbor KRAS mutations have revealed strong cooperation with the loss of LKB1 compared to that with the loss of p53 or Ink4a/Arf in terms of shorter tumor latency and greater levels of metastasis (26).”
BackgroundEnhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer
Komiya, T., Coxon, A. B., Park, Y., Chen, W.-D., Zajac‐Kaye, M., Meltzer, P. S., Karpova, T., & Kaye, F. J. (2009) · Oncogene · doi:10.1038/onc.2009.453 · Cited by 53
“…while LKB1 can cooperate with mutant K-ras in a mouse lung tumor model, LKB1 mutations are detected in human tumor samples that are either wildtype or mutant for K-ras, p53, and CDKN2a/arf/RB cancer genes suggesting that LKB1 tumorigenesis may not be dependent on these pathways (Ji et al., 2007).”
BackgroundInfluentialRole of p53 Family Proteins in Metformin Anti-Cancer Activities
Yi, Y., Zhang, W., Yi, J., & Xiao, Z. J. (2019) · Journal of Cancer · doi:10.7150/jca.30659 · Cited by 52
“In fact, knockout of LKB1 promotes K-RasG12D-induced lung cancer metastasis[102].”
BackgroundPavan, A., Bragadin, A. B., Calvetti, L., Ferro, A., Zulato, E., Attili, I., Nardo, G., Maso, A. D., Frega, S., Menin, A. G., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-674 · Cited by 49
“The oncogenic path primed by KRAS mutation is further boosted by LKB1 inactivation, which is able to increase metastatic potentials acting on the anchorage-dependent cell-growth (23) and tumor cell differentiation (63).”
Chong, C. R., & Chabner, B. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0286 · Cited by 47
Heightening Energetic Stress Selectively Targets LKB1-Deficient Non–Small Cell Lung Cancers
Momcilovic, M., McMickle, R., Abt, E., Seki, A., Simko, S. A., Magyar, C., Stout, D. B., Fishbein, M. C., Walser, T. C., Dubinett, S. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0797 · Cited by 46
“detailed examination of the lung tumor subtypes distribution (26).”
Kondo, S., Iwata, S., Yamada, T., Inoue, Y., Ichihara, H., Kichikawa, Y., Katayose, T., Souta-Kuribara, A., Yamazaki, H., Hosono, O., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2162 · Cited by 46
“Indeed, some of these studies described NEDD9 as one of the metastatic signature (25, 27).”
BackgroundKonen, J. M., Wilkinson, S. C., Lee, B., Fu, H., Zhou, W., Jiang, Y., & Marcus, A. I. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-08-0569 · Cited by 49
“Complete LKB1 loss in a Kras G12D -driven genetically engineered mouse model (GEMM) of lung cancer led to increased tumor burden, shortened survival time, and increased metastasis compared with Kras G12D mutant mice (Ji et al ., 2007).”
Wang, Y., Li, N., Jiang, W., Deng, W., Ye, R., Cai, X., Qiao, Y., Sharma, A., Zhang, M., Hung, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1489 · Cited by 46
“In one study of genetically modified mice, Kras-Lkb1–mutated cells produced squamous tumors, whereas Kras or Kras-p53–mutated cells produced adenocarcinomas (15).”
BackgroundTargeting mutated GTPase KRAS in tumor therapies
Fan, G., Lou, L., Song, Z., Zhang, X., & Xiong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113816 · Cited by 48
Memmott, R. M., Gills, J. J., Hollingshead, M., Powers, M. C., Chen, Z., Kemp, B., Kozikowski, A., & Dennis, P. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3091 · Cited by 44
“More recently, LKB1 mutations have also been described in f20% of squamous cell carcinomas and f10% of large cell carcinomas of the lung ( 4 ).”
BackgroundTumor Suppression by LKB1: SIK-ness Prevents Metastasis
Shaw, R. J. (2009) · Science Signaling · doi:10.1126/scisignal.286pe55 · Cited by 60
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.